Your browser doesn't support javascript.
loading
International trends in clozapine use: a study in 17 countries.
Bachmann, C J; Aagaard, L; Bernardo, M; Brandt, L; Cartabia, M; Clavenna, A; Coma Fusté, A; Furu, K; Garuoliené, K; Hoffmann, F; Hollingworth, S; Huybrechts, K F; Kalverdijk, L J; Kawakami, K; Kieler, H; Kinoshita, T; López, S C; Machado-Alba, J E; Machado-Duque, M E; Mahesri, M; Nishtala, P S; Piovani, D; Reutfors, J; Saastamoinen, L K; Sato, I; Schuiling-Veninga, C C M; Shyu, Y-C; Siskind, D; Skurtveit, S; Verdoux, H; Wang, L-J; Zara Yahni, C; Zoëga, H; Taylor, D.
Afiliação
  • Bachmann CJ; Freelance Researcher, Marburg, Germany.
  • Aagaard L; Life Science Team, Bech-Bruun Law Firm, Copenhagen, Denmark.
  • Bernardo M; Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, and Hospital Clínic, Department of Medicine, Barcelona University, and Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
  • Brandt L; Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Cartabia M; Pharmacoepidemiology Unit, Department of Public Health, IRCCS Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.
  • Clavenna A; Pharmacoepidemiology Unit, Department of Public Health, IRCCS Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.
  • Coma Fusté A; Pharmacy Department of Barcelona Health Region, Catalan Health Service (CatSalut), Barcelona, Spain.
  • Furu K; Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Garuoliené K; Medicines Reimbursement Department, National Health Insurance Fund of the Republic of Lithuania, Vilnius, Lithuania.
  • Hoffmann F; Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University, Vilnius, Lithuania.
  • Hollingworth S; Department of Health Services Research, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.
  • Huybrechts KF; School of Pharmacy, University of Queensland, Woolloongabba, Qld, Australia.
  • Kalverdijk LJ; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Kawakami K; University of Groningen, University Medical Center Groningen, Department of Psychiatry, the Netherlands.
  • Kieler H; Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
  • Kinoshita T; Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • López SC; Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
  • Machado-Alba JE; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A., Pereira, Colombia.
  • Machado-Duque ME; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A., Pereira, Colombia.
  • Mahesri M; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A., Pereira, Colombia.
  • Nishtala PS; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Piovani D; New Zealand's National School of Pharmacy, University of Otago, Dunedin, New Zealand.
  • Reutfors J; Pharmacoepidemiology Unit, Department of Public Health, IRCCS Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.
  • Saastamoinen LK; Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Sato I; Kela Research, The Social Insurance Institution, Helsinki, Finland.
  • Schuiling-Veninga CCM; Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
  • Shyu YC; Unit of Pharmacotherapy, -Epidemiology and -Economics, Department of Pharmacy, University of Groningen, Groningen, the Netherlands.
  • Siskind D; Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Skurtveit S; Institute of Molecular Biology, Academia Sinica, Taipei, Qld, Taiwan.
  • Verdoux H; Department of Nutrition, Chang Gung University of Science and Technology, Kwei-Shan, Taiwan.
  • Wang LJ; School of Medicine, University of Queensland, Woolloongabba, Qld, Australia.
  • Zara Yahni C; Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Zoëga H; University Bordeaux, INSERM, Bordeaux Population Health Research Center, team Pharmaco-epidemiology, UMR 1219, F-33000, Bordeaux, France.
  • Taylor D; Department of Child & Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Acta Psychiatr Scand ; 136(1): 37-51, 2017 07.
Article em En | MEDLINE | ID: mdl-28502099
ABSTRACT

OBJECTIVE:

There is some evidence that clozapine is significantly underutilised. Also, clozapine use is thought to vary by country, but so far no international study has assessed trends in clozapine prescribing. Therefore, this study aimed to assess clozapine use trends on an international scale, using standardised criteria for data analysis.

METHOD:

A repeated cross-sectional design was applied to data extracts (2005-2014) from 17 countries worldwide.

RESULTS:

In 2014, overall clozapine use prevalence was greatest in Finland (189.2/100 000 persons) and in New Zealand (116.3/100 000), and lowest in the Japanese cohort (0.6/100 000), and in the privately insured US cohort (14.0/100 000). From 2005 to 2014, clozapine use increased in almost all studied countries (relative increase 7.8-197.2%). In most countries, clozapine use was highest in 40-59-year-olds (range 0.6/100 000 (Japan) to 344.8/100 000 (Finland)). In youths (10-19 years), clozapine use was highest in Finland (24.7/100 000) and in the publicly insured US cohort (15.5/100 000).

CONCLUSION:

While clozapine use has increased in most studied countries over recent years, clozapine is still underutilised in many countries, with clozapine utilisation patterns differing significantly between countries. Future research should address the implementation of interventions designed to facilitate increased clozapine utilisation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prescrições de Medicamentos / Antipsicóticos / Clozapina / Uso de Medicamentos Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prescrições de Medicamentos / Antipsicóticos / Clozapina / Uso de Medicamentos Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article